tradingkey.logo

直觉外科

ISRG
查看详细走势图
559.520USD
+17.200+3.17%
收盘 12/15, 16:00美东报价延迟15分钟
198.57B总市值
72.75市盈率 TTM

直觉外科

559.520
+17.200+3.17%
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

+3.17%

5天

-1.30%

1月

+1.82%

6月

+9.24%

今年开始到现在

+7.20%

1年

+3.70%

查看详细走势图

TradingKey 直觉外科股票评分

单位: USD 更新时间: 2025-12-12

操作建议

直觉外科当前公司基本面数据相对非常健康,增长潜力很大。当前估值合理,在医疗设备与耗材行业排名56/208位。机构持股占比非常高,近一月多位分析师给出公司评级为买入。最高目标价601.41。中期看,股价处于上升通道。近一个月,市场表现一般,但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间,可以做区间波段操作。

直觉外科评分

相关信息

行业排名
56 / 208
全市场排名
142 / 4592
所属行业
医疗设备与耗材

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

分析师目标

根据 34 位分析师
买入
评级
601.410
目标均价
+6.09%
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议

直觉外科亮点

亮点风险
Intuitive Surgical, Inc. develops, manufactures, and markets da Vinci surgical systems and the Ion endoluminal system. The Company specializes in invasive care and robotic-assisted surgery. Its technologies include the da Vinci surgical systems and the Ion endoluminal system. The da Vinci surgical system is designed to enable surgeons to perform a range of surgical procedures within its targeted general surgery, urologic, gynecologic, cardiothoracic, and head and neck specialties and consists of a surgeon's console or consoles, a patient-side cart, and a high-performance vision system. The Ion endoluminal system is a flexible, robotic-assisted, catheter-based platform for which the cleared indication is minimally invasive biopsies in the lung and consists of a system cart, a controller, a catheter, and a vision probe. Its Ion system extends its commercial offering beyond surgery into diagnostic and endoluminal procedures.
业绩高增长
公司营业收入稳步增长,连续3年增长34.23%
利润高增长
公司净利润处于行业前列,最新年度总收入8.35B美元
估值合理
公司最新PE估值70.52,处于3年历史合理位
机构减仓
最新机构持股310.67M股,环比减少3.53%
布兰德斯投资公司持仓
明星投资者布兰德斯投资公司持仓,最新持仓市值481.00

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

直觉外科简介

Intuitive Surgical, Inc. develops, manufactures, and markets da Vinci surgical systems and the Ion endoluminal system. The Company specializes in invasive care and robotic-assisted surgery. Its technologies include the da Vinci surgical systems and the Ion endoluminal system. The da Vinci surgical system is designed to enable surgeons to perform a range of surgical procedures within its targeted general surgery, urologic, gynecologic, cardiothoracic, and head and neck specialties and consists of a surgeon's console or consoles, a patient-side cart, and a high-performance vision system. The Ion endoluminal system is a flexible, robotic-assisted, catheter-based platform for which the cleared indication is minimally invasive biopsies in the lung and consists of a system cart, a controller, a catheter, and a vision probe. Its Ion system extends its commercial offering beyond surgery into diagnostic and endoluminal procedures.
公司代码ISRG
公司直觉外科
CEORosa (David J)
网址https://www.intuitive.com/en-us/about-us/company

常见问题

直觉外科(ISRG)的当前股价是多少?

直觉外科(ISRG)的当前股价是 559.520。

直觉外科的股票代码是什么?

直觉外科的股票代码是ISRG。

直觉外科股票的52周最高点是多少?

直觉外科股票的52周最高点是616.000。

直觉外科股票的52周最低点是多少?

直觉外科股票的52周最低点是425.000。

直觉外科的市值是多少?

直觉外科的市值是198.57B。

直觉外科的净利润是多少?

直觉外科的净利润为2.32B。

现在直觉外科(ISRG)的股票是买入、持有还是卖出?

根据分析师评级,直觉外科(ISRG)的总体评级为买入,目标价格为601.410。

直觉外科(ISRG)股票的每股收益(EPS TTM)是多少

直觉外科(ISRG)股票的每股收益(EPS TTM)是7.691。
KeyAI